Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Circio Holding

Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Vain PDF

126 päivää sitten

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 2 t sitten
    ·
    Interesting read before the R&D webcast on September 1st This article came out today and is worth reading for everyone who follows Circio and circRNA: "RNA's comeback tour – Cell & Gene Therapy Review" https://www.cellgenetherapyreview.com/3975-Featured-Articles/627533-RNA-s-comeback-tour/ The interesting thing is not just that circRNA is mentioned, but how the entire RNA landscape is described as entering a new phase – especially within delivery, in vivo cell engineering, and in vivo CAR-T. The article highlights, among other things: • BMS bought Orbital for $1.5 billion • Lilly bought Orna for up to $2.4 billion • J&J paid $785 million upfront to Sail and received an option for an additional $2.58 billion • Several large pharma players are investing heavily in RNA + LNP + in vivo cell engineering And then Circio comes in as a slightly different variant. Wiklund points to the difference between regular mRNA/circRNA which is delivered ready in a dose, and circVec where the cell itself continuously produces and circularizes RNA. The article also mentions Circio's reported up to six months of expression in lymphocytes in vivo. Even more interesting is the comment that Circio is now testing circVec together with Acuitas and other delivery companies to combine the long expression profile with targeted delivery. It is precisely this combination that I find interesting to follow going forward: delivery → cell-specificity → expression → duration → effect → safety If Circio manages to document that circVec can actually provide a significant advantage on these points, one begins to approach a platform that can potentially be used across several programs – not just a single candidate. And that makes the webcast on September 1st extra interesting, especially since Circio itself has said that they will come with new data and a comprehensive R&D, BD, and financial update. It will be exciting to see how much of this actually begins to materialize in data.
    25 min sitten
    ·
    Cool! Where do you have the webcast from Sept 1st from?
  • 5 t sitten · Muokattu
    ·
    Today's large price swings and 103 mill in turnover can be interpreted positively. The reaction triggered by Moderna news in the USA shows how sensitive the market now is to news in Circio. When a non-company-specific news from the USA makes investors press the buy button, what do you think happens when concrete news arrives in about 1 week in Circio itself???? 😊
    4 t sitten
    ·
    Do you know that concrete news is coming?
  • 5 t sitten
    ·
    Many waiting for news here? I have received all the news I need. Unique results in tests, cooperation agreements with both Spanish and American universities, and cooperation with others in the industry. I'm just waiting for 1 new big piece of news. Acquisition! And when it comes, it's too late to jump on the train. Or should we say the rocket. While I wait for this news, I'm filling up with every spare krone. Everything under 20 kr is cheap!!
    2 t sitten
    ·
    Anyway, it's boring to be those who sold modena for 60 dollars yesterday when it opened like it did today. Absolutely wild how high the turnover has been today. Here, the potential is not just 150% up when the clock ticks 09:00 in the morning, but potentially higher with the right news. As Erik said 6 months back, this will go 10-bagger.
  • 7 t sitten
    ·
    An unhealthy culture has been created in this stock. People are unable to value the company and traders are running wild due to an interest.
    4 t sitten
    ·
    It has become a widespread negative culture that some here try to dictate what people should think, and now people are also expected to value the company .. you can think absolutely what you want , but interfering with what people who own this stock do ... .. that's just not okay.
  • 8 t sitten
    ·
    We can hope that Circio will come with news of the same caliber sometime in the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

126 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 2 t sitten
    ·
    Interesting read before the R&D webcast on September 1st This article came out today and is worth reading for everyone who follows Circio and circRNA: "RNA's comeback tour – Cell & Gene Therapy Review" https://www.cellgenetherapyreview.com/3975-Featured-Articles/627533-RNA-s-comeback-tour/ The interesting thing is not just that circRNA is mentioned, but how the entire RNA landscape is described as entering a new phase – especially within delivery, in vivo cell engineering, and in vivo CAR-T. The article highlights, among other things: • BMS bought Orbital for $1.5 billion • Lilly bought Orna for up to $2.4 billion • J&J paid $785 million upfront to Sail and received an option for an additional $2.58 billion • Several large pharma players are investing heavily in RNA + LNP + in vivo cell engineering And then Circio comes in as a slightly different variant. Wiklund points to the difference between regular mRNA/circRNA which is delivered ready in a dose, and circVec where the cell itself continuously produces and circularizes RNA. The article also mentions Circio's reported up to six months of expression in lymphocytes in vivo. Even more interesting is the comment that Circio is now testing circVec together with Acuitas and other delivery companies to combine the long expression profile with targeted delivery. It is precisely this combination that I find interesting to follow going forward: delivery → cell-specificity → expression → duration → effect → safety If Circio manages to document that circVec can actually provide a significant advantage on these points, one begins to approach a platform that can potentially be used across several programs – not just a single candidate. And that makes the webcast on September 1st extra interesting, especially since Circio itself has said that they will come with new data and a comprehensive R&D, BD, and financial update. It will be exciting to see how much of this actually begins to materialize in data.
    25 min sitten
    ·
    Cool! Where do you have the webcast from Sept 1st from?
  • 5 t sitten · Muokattu
    ·
    Today's large price swings and 103 mill in turnover can be interpreted positively. The reaction triggered by Moderna news in the USA shows how sensitive the market now is to news in Circio. When a non-company-specific news from the USA makes investors press the buy button, what do you think happens when concrete news arrives in about 1 week in Circio itself???? 😊
    4 t sitten
    ·
    Do you know that concrete news is coming?
  • 5 t sitten
    ·
    Many waiting for news here? I have received all the news I need. Unique results in tests, cooperation agreements with both Spanish and American universities, and cooperation with others in the industry. I'm just waiting for 1 new big piece of news. Acquisition! And when it comes, it's too late to jump on the train. Or should we say the rocket. While I wait for this news, I'm filling up with every spare krone. Everything under 20 kr is cheap!!
    2 t sitten
    ·
    Anyway, it's boring to be those who sold modena for 60 dollars yesterday when it opened like it did today. Absolutely wild how high the turnover has been today. Here, the potential is not just 150% up when the clock ticks 09:00 in the morning, but potentially higher with the right news. As Erik said 6 months back, this will go 10-bagger.
  • 7 t sitten
    ·
    An unhealthy culture has been created in this stock. People are unable to value the company and traders are running wild due to an interest.
    4 t sitten
    ·
    It has become a widespread negative culture that some here try to dictate what people should think, and now people are also expected to value the company .. you can think absolutely what you want , but interfering with what people who own this stock do ... .. that's just not okay.
  • 8 t sitten
    ·
    We can hope that Circio will come with news of the same caliber sometime in the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

126 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 2 t sitten
    ·
    Interesting read before the R&D webcast on September 1st This article came out today and is worth reading for everyone who follows Circio and circRNA: "RNA's comeback tour – Cell & Gene Therapy Review" https://www.cellgenetherapyreview.com/3975-Featured-Articles/627533-RNA-s-comeback-tour/ The interesting thing is not just that circRNA is mentioned, but how the entire RNA landscape is described as entering a new phase – especially within delivery, in vivo cell engineering, and in vivo CAR-T. The article highlights, among other things: • BMS bought Orbital for $1.5 billion • Lilly bought Orna for up to $2.4 billion • J&J paid $785 million upfront to Sail and received an option for an additional $2.58 billion • Several large pharma players are investing heavily in RNA + LNP + in vivo cell engineering And then Circio comes in as a slightly different variant. Wiklund points to the difference between regular mRNA/circRNA which is delivered ready in a dose, and circVec where the cell itself continuously produces and circularizes RNA. The article also mentions Circio's reported up to six months of expression in lymphocytes in vivo. Even more interesting is the comment that Circio is now testing circVec together with Acuitas and other delivery companies to combine the long expression profile with targeted delivery. It is precisely this combination that I find interesting to follow going forward: delivery → cell-specificity → expression → duration → effect → safety If Circio manages to document that circVec can actually provide a significant advantage on these points, one begins to approach a platform that can potentially be used across several programs – not just a single candidate. And that makes the webcast on September 1st extra interesting, especially since Circio itself has said that they will come with new data and a comprehensive R&D, BD, and financial update. It will be exciting to see how much of this actually begins to materialize in data.
    25 min sitten
    ·
    Cool! Where do you have the webcast from Sept 1st from?
  • 5 t sitten · Muokattu
    ·
    Today's large price swings and 103 mill in turnover can be interpreted positively. The reaction triggered by Moderna news in the USA shows how sensitive the market now is to news in Circio. When a non-company-specific news from the USA makes investors press the buy button, what do you think happens when concrete news arrives in about 1 week in Circio itself???? 😊
    4 t sitten
    ·
    Do you know that concrete news is coming?
  • 5 t sitten
    ·
    Many waiting for news here? I have received all the news I need. Unique results in tests, cooperation agreements with both Spanish and American universities, and cooperation with others in the industry. I'm just waiting for 1 new big piece of news. Acquisition! And when it comes, it's too late to jump on the train. Or should we say the rocket. While I wait for this news, I'm filling up with every spare krone. Everything under 20 kr is cheap!!
    2 t sitten
    ·
    Anyway, it's boring to be those who sold modena for 60 dollars yesterday when it opened like it did today. Absolutely wild how high the turnover has been today. Here, the potential is not just 150% up when the clock ticks 09:00 in the morning, but potentially higher with the right news. As Erik said 6 months back, this will go 10-bagger.
  • 7 t sitten
    ·
    An unhealthy culture has been created in this stock. People are unable to value the company and traders are running wild due to an interest.
    4 t sitten
    ·
    It has become a widespread negative culture that some here try to dictate what people should think, and now people are also expected to value the company .. you can think absolutely what you want , but interfering with what people who own this stock do ... .. that's just not okay.
  • 8 t sitten
    ·
    We can hope that Circio will come with news of the same caliber sometime in the future.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt